This module uses fundamental data of Telix Pharmaceuticals to approximate its Piotroski F score. Telix Pharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Telix Pharmaceuticals. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Telix Pharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Telix
Piotroski F Score
Sale Purchase Of Stock
Change In Cash
Net Borrowings
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
Change To Netincome
Change To Liabilities
Change To Inventory
Investments
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Dividends Paid
End Period Cash Flow
Other Cashflows From Investing Activities
Issuance Of Capital Stock
Common Stock Shares Outstanding
Total Assets
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Liabilities And Stockholders Equity
Non Current Liabilities Total
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Common Stock
Short Long Term Debt Total
Other Current Liab
Other Liab
Net Tangible Assets
Non Currrent Assets Other
Other Assets
Good Will
Long Term Debt Total
Inventory
Other Current Assets
Other Stockholder Equity
Net Invested Capital
Short Long Term Debt
Accumulated Other Comprehensive Income
Net Working Capital
Short Term Debt
Intangible Assets
Property Plant Equipment
Current Deferred Revenue
Long Term Debt
Capital Stock
Non Current Liabilities Other
Capital Lease Obligations
Interest Expense
Other Operating Expenses
Operating Income
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Depreciation And Amortization
Selling General Administrative
Total Revenue
Gross Profit
Net Income From Continuing Ops
Ebit
Research Development
Cost Of Revenue
Net Income Applicable To Common Shares
Tax Provision
Net Interest Income
Interest Income
Selling And Marketing Expenses
Reconciled Depreciation
Probability Of Bankruptcy
At this time, Telix Pharmaceuticals' Short and Long Term Debt Total is comparatively stable compared to the past year. Long Term Debt Total is likely to gain to about 11.8 M in 2024, despite the fact that Net Debt is likely to grow to (100.5 M).
At this time, it appears that Telix Pharmaceuticals' Piotroski F Score is Inapplicable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Telix Pharmaceuticals is to make sure Telix is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Telix Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Telix Pharmaceuticals' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Telix Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Telix Pharmaceuticals in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Net Debt
(100.5 Million)
At this time, Telix Pharmaceuticals' Net Debt is comparatively stable compared to the past year.
About Telix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telix Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telix Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.